Undruggable | Amgen

Beginning with the introduction of aspirin at the start of the 20th century, there have been three major waves of innovation in drug discovery. Science has made incredible breakthroughs in treating and curing disease, and yet 85% of disease targets are still considered undruggable, which represents an ongoing barrier to discovering medicines for complex diseases like cancer and autoimmune conditions.

In this five-part series, Ray Deshaies, who has spent decades in academic research and is a senior vice president of Global Research at Amgen, hosts conversations with leading scientists to take a deep dive into the most promising new innovations to treat disease as we enter a fourth wave of innovation.

Listen in to learn how the current wave of discovery, led by new types of multispecific medicines, has the potential to radically alter our concept of how drugs can work and pave the way for new solutions.


The Next Wave of Drug Development with Ryan Potts, Ph.D., executive director, Research and head of Induced Proximity Platform at Amgen

The Biology of PROTACs with Craig Crews, Ph.D., professor of Molecular, Cellular and Developmental Biology, Yale

Discovery at the DNA Encoded Library with Alex Gouliaev, Ph.D., vice president, Amgen Research Copenhagen

The emerging IPP toolkit with Carolyn Bertozzi, Ph.D., professor of Chemistry, Stanford

Induced Proximity: Reason for Optimism in Treating Cancer and Beyond with David Reese, M.D., executive vice president, Research and Development, Amgen

Subscribe Below